From May 20 to 22, the first Eurasian International Medical Forum was held in Ekaterinburg. The event was dedicated to the 80th anniversary of Victory in the Great Patriotic War. The Forum brought together over 1,000 participants and 250 experts from Russia, India, China and Belarus. Medsintez Plant took an active part in scientific program of the Forum and demonstrated its latest developments in the field of import-substituting drugs.
The X (XXXI) National Diabetes Congress with international participation was held in Moscow from May 27 to 30, 2025. The event was dedicated to the topic «Diabetes mellitus – a non-infectious pandemic of the 21st century. Macro- and microvascular complications. Issues of interdisciplinary interaction». The Congress was dedicated to the 100th anniversary of the Russian Association of Endocrinologists, the Endocrinology Service of the Russian Federation and the Research Center for Endocrinology.
In May 2025, pharmaceutical plant Medsintez Plant LLC joined the leading enterprises that were awarded the status of National Champion based on the results of a comprehensive expert selection. Getting the status of National Champion is a significant event for Medsintez Plant, which emphasizes its contribution to the development of the pharmaceutical industry and strengthening the drug safety of Russia.
From April 15 to 18, Ekaterinburg hosted the 6th international specialized exhibition and forum Healthcare of the Urals–2025. This year, 130 companies from 34 cities of Russia and the Republic of Belarus took part in the event, presenting over 1000 units of medical equipment and goods. The residents of the Ural Biomedical Cluster were traditionally among the participants, as well as its collective member – the Association of Medical and Pharmaceutical Manufacturers of the Sverdlovsk Region.
Medsintez Plant LLC is a modern full-cycle biotechnological enterprise for development and production of pharmaceutical products complying with the international GMP requirements and ISO standards. The Medsintez Plant has been present on the Russian market for 20 years and is an active participant of drug import substitution programs in the Russian Federation.
The company produces genetically engineered and analogue human insulins Rosinsulin, a veterinary insulin Vinsuvet, a recombinant human follicle-stimulating hormone for the treatment of infertility Primapur, a recombinant human albumin, an innovative antiviral drug Triazavirin, hypoglycemic drugs Liraglutide and Semaglutide, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.
Main products of the enterprise are genetically engineered and analogue human insulins Rosinsulin, produced in cartridges, vials and pre-filled injection pens. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin Rosinsulin and analogue human insulins Rosinsulin Aspart R and Rosinsulin Glargine made of our own APIs. The plant also produces the first Russian veterinary species-specific insulin Vinsuvet, separately for cats and for dogs. In 2023, the Plant launched the production of a full cycle of hypoglycemic drugs for treating type II diabetes mellitus: Liraglutide and Semaglutide.
Triazavirin is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. Triazavirin is recommended by the Ministry of Health of the Russian Federation for treatment of influenza and ARVI in adults, and is the only direct-acting drug approved for prevention of COVID-19. Today, the company is developing a complex of antiviral drugs.
Primapur is the first Russian drug of recombinant human follicle-stimulating hormone for human infertility treatment, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur is available in the form of an easy-to-use disposable injection pen. Today, the company is developing other hormonal drugs, used in a complex of assisted reproductive technologies, such as recombinant human chorionic gonadotropin, Cetrorelix, which will ensure the drug safety in this area in Russia and enable it not to depend on import supplies.
In 2024 the full-cycle production of the world's first registered recombinant human albumin for widespread use in medicine was launched.
One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.
High-tech Russian production at the Medsintez Plant ensures a high level of quality and safety of manufactured medicines. The company’s products are supplied to all regions of Russia. The production capacity of the plant is enough to cover 100% of the country’s needs for vital insulin medications and drugs for the treatment of infertility, as well as to provide major support to the country during epidemics and pandemics of viral infections.
15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia
Тel.: +7 (34370) 2-50-61
e-mail: medsintez@mail.ru